Valeant’s CEO projects that a $1 billion portfolio of key products will help the drug maker fight debt and exclusivity challenges.
Valeant CEO Joseph Papa projects that a $1 billion portfolio of key products will help the drug maker fight debt and exclusivity challenges.
“We received an approval for, really, what we think are seven fabulous products,” Papa said on CNBC’s “Power Lunch.” “If all of these products get approved, we think it is going to be an over $1 billion opportunity.”
Papa took the reins of an embattled Valeant in 2016, amid accusations of fraud and price gouging in the company.